Xtane 25mg Tablet

• ​Early Breast Cancer Treatment
• Advanced Breast Cancer Treatment

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Xtane 25mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention. In in case of any unusual or severe side effects, immediately.

Some common side effects include:

• Headache
  
• Dizziness
  
• Rash
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Insomnia (difficulty sleeping)
• Fatigue / Weakness
• Increased sweating
• Hot flushes
• Depression
• Muscle pain / Joint pain / Back pain
• Bone pain / Fracture / Osteoporosis
• Carpal tunnel syndrome (numbness, tingling, hand pain)
• Paresthesia (tingling or pricking sensation)
• Itching (pruritus) / Urticaria
• Hair loss
• Decreased appetite / Increased appetite
• Peripheral edema (swelling in hands and feet)
• Allergic reactions / Difficulty breathing
• Low white blood cell count (lymphocytes, leukopenia)
• Low blood platelets (thrombocytopenia)
• High liver enzyme levels
  

• Doctor determines the exact dose and duration with Xtane 25mg Tablet as per the overall health condition of the patient.
• This tablet should be taken with food or after food, but at the fixed time every day to get effective results.
• Swallow it as a whole with a glass of water and do not crush, chew, or open it.

• Xtane 25mg Tablet is an anticancer medicine with Exemestane as an active ingredient.
• It belongs to the class of drugs known as aromatase inhibitors.
• It works by blocking the action of the enzyme responsible for the production of the female hormone estrogen to lower its amount in the body.
• It results in controlling the growth of cancer cells as some breast cancer cells require estrogen to multiply.

If you forget to take a dose of Xtane 25mg Tablet, consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., ... & Bliss, J. M. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11), 1081-1092. https://pubmed.ncbi.nlm.nih.gov/15014181/
• Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., ... & Coombes, R. C. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. The lancet oncology, 8(2), 119-127. https://pubmed.ncbi.nlm.nih.gov/17267326/
• Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., ... & Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine, 371(2), 107-118. https://pubmed.ncbi.nlm.nih.gov/24881463/
• Deeks, E. D., & Scott, L. J. (2009). Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs, 69(7), 889-918. https://pubmed.ncbi.nlm.nih.gov/19441873/
• Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., ... & Richardson, H. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine, 364(25), 2381-2391. https://pubmed.ncbi.nlm.nih.gov/21639806/